Bora CDMO Bora CDMO

X

Find the latest Drugs in Development and Pipeline Prospector News of Stemirna Therapeutics.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Stemirna Therapeutics
China Flag
Country
Country
China
Address
Address
Room 415, Building A 1088 Xinjinqiao Rd Pudong Xinqu, Shanghai Shi, China
Telephone
Telephone
021-61053499
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

SW1115C3 is a personalized cancer vaccine (PCV) consisting of mRNA encoding a patient's tumor-specific neoantigens. It is being evaluated for the treatment of solid tumors.


Lead Product(s): SW1115C3

Therapeutic Area: Oncology Product Name: SW1115C3

Highest Development Status: Phase IProduct Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 21, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Stemirna Therapeutics raised nearly $200 million to speed up the clinical study of its COVID-19 vaccine candidate, SW-0123. It is in phase I study in China and preclinical data have been published in Nature.


Lead Product(s): mRNA Covid-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: IND EnablingProduct Type: Vaccine

Partner/Sponsor/Collaborator: Sequoia Capital

Deal Size: $200.0 million Upfront Cash: Undisclosed

Deal Type: Financing June 03, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The potential vaccine, which Stemirna has started working on since January last year, is based on messenger RNA (mRNA) technology, Tibet Rhodiola Pharma, which is jointly developing the candidate with Stemirna.


Lead Product(s): mRNA Covid-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: IND EnablingProduct Type: Vaccine

Partner/Sponsor/Collaborator: Tibet Rhodiola Pharmaceutical

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 05, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The pilot testing of the vaccine for novel coronavirus, will be focused on animal toxicology and the vaccine's effectiveness. Clinical trials are expected to start in mid-April.


Lead Product(s): COVID-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 17, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY